The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Merrimack; Pfizer
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Araxes Pharma; AstraZeneca; Biocartis; Boehringer Ingelheim; Chugai Pharma; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Rudolf M. Huber
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Guardant Health; Lilly; Merck; Mologen; Novartis; Pfizer; Roche; Takeda
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Janssen; Lilly
Speakers' Bureau - Genentech
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epic Sciences (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Janssen Oncology
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - EMD Serono (Inst); Merck (Inst)
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Fred R. Hirsch
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; HTG Molecular Diagnostics; Lilly; Merck; Pfizer; Roche; Ventana Medical Systems
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Lilly/ImClone (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Geoffrey Kuesters
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Alena Zalutskaya
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Patents, Royalties, Other Intellectual Property - US 8837796 B1 “Systems and methods for monitoring a dermatologic condition”
Travel, Accommodations, Expenses - Merrimack
 
Sergio Santillana
Employment - ARIAD; Merrimack
Leadership - ARIAD; Merrimack
Stock and Other Ownership Interests - ARIAD; Merrimack
Consulting or Advisory Role - Akamara Therapeutics; Clarus Ventures
Patents, Royalties, Other Intellectual Property - Patent related to work in Takeda (2015-2016) submitted for approval
Travel, Accommodations, Expenses - Akamara Therapeutics; ARIAD; Merrimack
 
J. Marc Pipas
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Roche Canada (Inst)